New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in ...

Over a short period in the late 1990s, three groups converged on the discovery of a neuropeptide system, centred in the dorsolateral hypothalamus, that regulates arousal states, influences feeding ...

Background: IGF1R is a receptor tyrosine kinase which is overexpressed in many primary tumor cells, including breast, colon, lung and prostate cancers. Activation of this signaling pathway induces ...

The famous "bible" of chemistry, The Merck Index, is to join the highly acclaimed publishing portfolio of the Royal Society of Chemistry. In buying the rights to the iconic reference book, where ...

No new safety signals were identified. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; KEYNOTE-689 ClinicalTrials.gov number, NCT03765918.) ...

UBS upgraded Alkermes (NASDAQ: ALKS) from Neutral to Buy on Tuesday, raising its price target to $42.00 from $33.00. The upgrade reflects UBS’s growing confidence in the company’s orexin receptor drug ...

Merck & Co., Inc. (NYSE:MRK) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Cantor Fitzgerald reaffirmed its Neutral rating on Merck & Co., Inc.

UBS upgraded Alkermes (NASDAQ: ALKS) from Neutral to Buy on Tuesday, raising its price target to $42.00 from $33.00. The upgrade reflects UBS’s growing confidence in the company’s orexin ...

Analyst Ratings Published 06/17/2025, 05:14 AM 0 UBS upgrades Alkermes stock rating on orexin treatment potential ALKS -1.53% ...

The U.S. Supreme Court on Monday denied a petition for a writ of certiorari filed by the drug company Merck Sharp & Dohme Corp., bringing to a close a decade-long legal battle that had stalled ...

Orexin is a neuropeptide that regulates the sleep-wake cycle, leading to arousal and promoting wakefulness. Targeting the orexin pathway with novel orexin receptor 2 (OX2R) agonists represents a ...